Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T‐Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease

On November 15, 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended the extension of indication for blinatumomab to include the treatment of adults with minimal residual disease (MRD) positive B‐cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab was authorized to...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncologist
Main Authors: Ali, Sahra, Moreau, Alexandre, Melchiorri, Daniela, Camarero, Jorge, Josephson, Filip, Olimpier, Odoardo, Bergh, Jonas, Karres, Dominik, Tzogani, Kyriaki, Gisselbrecht, Christian, Pignatti, Francesco
格式: Artigo
語言:Inglês
出版: John Wiley & Sons, Inc. 2019
主題:
Regulatory Issues: EMA
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160312/
https://ncbi.nlm.nih.gov/pubmed/32297447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0559
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍